Levoxadrol is an active enantiomer of dexoxadrol.

Bristol-Myers Squibb developed BMS-188797 for the potential treatment of solid tumors. BMS-188797 causes G2/M cell cycle arrest and exhibits potent antiproliferative activity against human tumor cell. BMS-188797 in combination with cisplatin successfully has passed phase I clinical and has been recommended for further phase II trials. However, further development has been halted.

Eniluracil (5-ethynyluracil, GW 776, 776C85) is a potent irreversible inhibitor of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU), the most widely used drug in cancer chemotherapy. Eniluracil increases the oral bioavailability of 5-FU to 100%, facilitating uniform absorption and predictable toxicity. Eniluracil was being developed as a novel modulator of 5-FU for the treatment of cancer.

Tibenzate is a thiobenzoic acid derivative disclosed in Merck & Co., Inc. patent application. Topically applied Tibenzate shows high acaricidal activity, especially against itch mites (Sarcoptes scabiei) and their eggs. Tibenzate shows some level of antimicrobial activity against S.aureus, P.aeruginosa, and C.albicans.

Tibalosin is a phenylethylamine derivative patented by Continental Pharma as a potent vasodilator. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. In preclinical models, Tibalosin exerts favor influences on arterial pressure in the hypertensive animal. The drug has acceptable toxicity in experimental animals and has been well tolerated by normal human subjects in daily doses of up to 200 mg.

Tioxamast is an inhibitor of the release of histamine from the mast cell. Tioxamast decreased IgE- and IgG-dependent passive cutaneous anaphylaxis in rats at doses having no effect on histamine- and serotonin-induced capillary permeability. It has powerful oral anti-allergic properties in immediate hypersensitivity models in rats. Tioxamast was inactive against reverse passive Arthus pleurisy induced in rats by rabbit anti-bovine-albumin serum. Tioxamast inhibits the synthesis in vitro of leukotriene B4 (LTB4) by peritoneal neutrophils from rats stimulated by A23187). At higher tioxamast concentrations, metabolites of the cyclo-oxygenase pathway are inhibited at concentrations of the same order of magnitude as those that inhibit Naja naja phospholipase A2. Tioxamast also reduces the production of free radicals by leukocytes from the pleural cavity of rats which had phagocytosed opsonized zymosan. The anti-inflammatory and antiallergic effect of tioxamast makes it a potentially useful drug in the treatment of allergies in humans.

Tiodazosin is a newly developed antihypertensive agent, structurally related to prazosin. Prazosin and tiodazosin administrated intravenously to anesthetized rats, are equally effective hypotensive agents, but that the hypotensive potency of prazosin is greater than that of tiodazosin. However, chronic administration of equivalent doses of the two compounds for 25 and 52 days via the drinking water indicated approximately equivalent, sustained reductions in blood pressure. Furthermore, at the end of the 52-day chronic dosing period tiodazosin caused appreciably less alpha-adrenergic receptor antagonist activity than prazosin as assessed by the norepinephrine dose-pressor response profiles.

Tivanidazole is metronidazole derivative. It is antiprotozoal drug. Tivanidazole was used as trichomonacide.

Tisocromide exerts antihypoxic and antidepressant action. The details regarding mechanism of action and use are not available.

Tivirapine, also known as R-86183, is a HIV-1 specific reverse transcriptase inhibitor. It inhibits the replication of HIV-1, but not HIV-2, in a variety of CD4+ T-cell lines and peripheral blood lymphocytes. Whereas an HIV-1 strain containing the Leu-100-->Ile mutation in the RT gene is about 400-fold less susceptible, R86183 still inhibits the replication of an HIV-1 strain containing the Tyr-181-->Cys RT mutation by 50% at a concentration of 130 nM. Tivirapine had been in phase I clinical trial for the treatment of HIV-1 infection. However, this development was discontinued.